Why the study?
Does glibenclamide act as an antagonist of the thromboxane A2 receptor in dog coronary arteries in vitro?
Does glibenclamide act as an antagonist of the thromboxane A2 receptor in dog coronary arteries in vitro?
Glibenclamide acts as a competitive antagonist of the thromboxane A2 receptor in dog coronary arteries, an additional property to consider in smooth muscle studies.
Answers are grounded in this paper and cite their sources.
May influence interpretation of glibenclamide in vascular studies; leaves open translational relevance beyond canine coronary arteries in vitro.
Glibenclamide, a sulphonylurea oral hypoglycaemic agent is a widely used antagonist of cromakalim-activated K+ channels in smooth muscle. 2. In isolated ring segments of the large circumflex coronary artery from the dog, glibenclamide (1-30 microM) caused a concentration-dependent reduction in both spontaneous isometric force and contractions induced by U46619, a thromboxane A2-mimetic. 3. Glibenclamide behaved as a competitive antagonist of U46619 with an estimated pKB (-log KB) value of 6.2 by Schild regression analysis (slope 1.07). 4. Glibenclamide (30 microM) was apparently selective since it had no effect on the concentration-contraction curves to endothelin-1, noradrenaline or KCl. 5. We suggest that this additional property of glibenclamide should be considered in any smooth muscle study where active force is raised by either the exogenous application or endogenous generation of thromboxane A2.
No takes yet. Share an insight, caveat, or question.
Cocks et al. (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: